These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37991392)

  • 1. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants.
    Hindley B; Lip GYH; McCloskey AP; Penson PE
    Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):911-923. PubMed ID: 37991392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure.
    Padrini R
    Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):1-12. PubMed ID: 30167998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
    Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal agents for current and forthcoming direct oral anticoagulants.
    van Es N; De Caterina R; Weitz JI
    Eur Heart J; 2023 May; 44(20):1795-1806. PubMed ID: 36988142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
    Lagoutte-Renosi J; Le Poupon J; Girard A; Montange D; Davani S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():43-49. PubMed ID: 30292948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review.
    Zhao Y; Guo M; Li D; Xu W; Pan C; He C; Cui X
    Clin Appl Thromb Hemost; 2023; 29():10760296231153638. PubMed ID: 36760080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement and reversal of the direct oral anticoagulants.
    Samuelson BT; Cuker A
    Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Italian intersociety consensus on DOAC use in internal medicine.
    Prisco D; Ageno W; Becattini C; D'Angelo A; Davì G; De Cristofaro R; Dentali F; Di Minno G; Falanga A; Gussoni G; Masotti L; Palareti G; Pignatelli P; Santi RM; Santilli F; Silingardi M; Tufano A; Violi F; ; ;
    Intern Emerg Med; 2017 Apr; 12(3):387-406. PubMed ID: 28191610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of direct oral anticoagulants in daily practice.
    Almarshad F; Alaklabi A; Bakhsh E; Pathan A; Almegren M
    Am J Blood Res; 2018; 8(4):57-72. PubMed ID: 30697449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Direct Oral Anticoagulants (DOAC) and Their Use Today.
    Schwarb H; Tsakiris DA
    Dent J (Basel); 2016 Mar; 4(1):. PubMed ID: 29563447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants.
    Benamouzig R; Guenoun M; Deutsch D; Fauchier L
    Cardiovasc Drugs Ther; 2022 Oct; 36(5):973-989. PubMed ID: 34143317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating pharmacokinetic drug-drug interactions of direct oral anticoagulants in patients with renal dysfunction.
    Hanigan S; Park JM
    Expert Opin Drug Metab Toxicol; 2022 Mar; 18(3):189-202. PubMed ID: 35543017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New oral anticoagulants: comparative pharmacology with vitamin K antagonists.
    Scaglione F
    Clin Pharmacokinet; 2013 Feb; 52(2):69-82. PubMed ID: 23292752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dilemmas Related to Direct-Acting Oral Anticoagulant Administration in Patients With Extreme Obesity.
    Erstad BL; Barletta JF
    Ann Pharmacother; 2023 Jun; 57(6):727-737. PubMed ID: 36258660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review.
    Edwina AE; Dia N; Dreesen E; Vanassche T; Verhamme P; Spriet I; Van der Linden L; Tournoy J
    Clin Pharmacokinet; 2023 Mar; 62(3):351-373. PubMed ID: 36862336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
    Xu W; Lv M; Wu S; Jiang S; Zeng Z; Fang Z; Qian J; Chen M; Chen J; Zhang J
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):363-377. PubMed ID: 34436708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.